These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 16781242)

  • 1. Cost-effectiveness of cholesterol-lowering therapy with pravastatin in patients with previous acute coronary syndromes aged 65 to 74 years compared with younger patients: results from the LIPID study.
    Tonkin AM; Eckermann S; White H; Friedlander D; Glasziou P; Magnus P; Kirby A; Mulray S; Denton M; Sallaberger M; Hunt D; Simes J;
    Am Heart J; 2006 Jun; 151(6):1305-12. PubMed ID: 16781242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacoeconomic evaluation of pravastatin in coronary secondary prevention in patients with myocardial infarct or unstable angina pectoris. An analysis based on the LIPID Study].
    Szucs TD; Bertel O; Darioli R; Gutzwiller F; Mordasini R
    Praxis (Bern 1994); 2000 Apr; 89(18):745-52. PubMed ID: 10823012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels.
    Tsevat J; Kuntz KM; Orav EJ; Weinstein MC; Sacks FM; Goldman L
    Am Heart J; 2001 May; 141(5):727-34. PubMed ID: 11320359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.
    Nagata-Kobayashi S; Shimbo T; Matsui K; Fukui T
    Int J Cardiol; 2005 Sep; 104(2):213-23. PubMed ID: 16168816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute coronary syndromes in Europe: 1-year costs and outcomes.
    Taylor MJ; Scuffham PA; McCollam PL; Newby DE
    Curr Med Res Opin; 2007 Mar; 23(3):495-503. PubMed ID: 17355731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incremental benefit and cost-effectiveness of high-dose statin therapy in high-risk patients with coronary artery disease.
    Chan PS; Nallamothu BK; Gurm HS; Hayward RA; Vijan S
    Circulation; 2007 May; 115(18):2398-409. PubMed ID: 17452609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT).
    Mark DB; Nelson CL; Anstrom KJ; Al-Khatib SM; Tsiatis AA; Cowper PA; Clapp-Channing NE; Davidson-Ray L; Poole JE; Johnson G; Anderson J; Lee KL; Bardy GH;
    Circulation; 2006 Jul; 114(2):135-42. PubMed ID: 16818817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
    Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden.
    Olsson A; Casciano R; Stern L; Svangren P
    Int J Cardiol; 2004 Jul; 96(1):51-7. PubMed ID: 15203261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of fluvastatin following successful first percutaneous coronary intervention.
    Delea TE; Jacobson TA; Serruys PW; Edelsberg JS; Oster G
    Ann Pharmacother; 2005 Apr; 39(4):610-6. PubMed ID: 15741421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue plasminogen activator was cost-effective compared to streptokinase in only selected patients with acute myocardial infarction.
    Kent DM; Vijan S; Hayward RA; Griffith JL; Beshansky JR; Selker HP
    J Clin Epidemiol; 2004 Aug; 57(8):843-52. PubMed ID: 15485737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of a cost-effectiveness study within a randomized trial: the LIPID Trial for Secondary Prevention of IHD. Long-term Intervention with Pravastatin in Ischemic Heart disease.
    Glasziou PP; Simes RJ; Hall J; Donaldson C
    Control Clin Trials; 1997 Oct; 18(5):464-76. PubMed ID: 9315428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial].
    Szucs TD; Berger K; März W; Schäfer JR
    Herz; 2000 Aug; 25(5):487-94. PubMed ID: 10992997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of cholesterol-lowering drugs: a review of the evidence.
    Thorvik E; Aursnes I; Kristiansen IS; Waaler HT
    Wien Klin Wochenschr; 1996; 108(8):234-43. PubMed ID: 8686314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial.
    Henriksson M; Epstein DM; Palmer SJ; Sculpher MJ; Clayton TC; Pocock SJ; Henderson RA; Buxton MJ; Fox KA
    Heart; 2008 Jun; 94(6):717-23. PubMed ID: 18032459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
    Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
    J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
    Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.